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Abstract
Background: This prospective, open-label phase II study assessed the impact of liver-directed therapy with selective
internal radiation therapy (SIRT) and systemic chemotherapy on progression-free survival (PFS) in liver-dominant
metastatic pancreatic adenocarcinoma.
Methods: Patients received yttrium-90-labelled (90Y) resin microspheres (SIR-Spheres; Sirtex Medical Limited, Sydney,
Australia) as a single procedure on day 2 of the first weekly cycle of 5-fluorouracil (5FU; 600 mg/m2) with the option to
switch to gemcitabine (1000 mg/m2) after 8 weeks of 5FU. Statistical analysis was conducted using Microsoft Excel
(Microsoft Corporation, Redmond, Washington, USA). The primary endpoint of the study was PFS in the liver, with a
median of ≥16 weeks defined as the threshold for clinical significance. PFS and overall survival (OS) were summarised
by the Kaplan-Meier method using non-parametric estimates of the survivor function.
Results: Fourteen eligible patients were enrolled; ten had primary tumour in situ and eight had liver-only metastases.
Patients received a median 90Y activity of 1.1 GBq and 8 weekly doses of 5FU; seven patients received a median of two
doses of gemcitabine. Disease control in the liver was 93 % (two confirmed partial responses [PR], one unconfirmed PR,
ten stable disease). Median reduction in cancer antigen 19–9 was 72 %. Median PFS was 5.2 months in the liver, which
met the primary endpoint of the study, and 4.4 months at any site. PFS was prolonged in those with a resected primary
compared with patients with primary in situ (median 7.8 vs. 3.4 months; p = 0.017). Median OS was 5.5 months overall
and 13.6 months in patients with a resected primary. Grade 3/4 adverse events occurred in eight (57 %) patients during
days 0–60. There was one sudden death and another patient who died from possible treatment-related liver failure
7.0 months after SIRT.
Conclusions: SIRT and chemotherapy appears to be an effective treatment for liver metastases from pancreatic cancer,
likely to be of most benefit in selected patients with a resected primary tumour and liver only disease. Significant toxicity
was observed and the safety of this approach in patients with metastatic pancreatic cancer will need to be confirmed in
subsequent studies. Further study is warranted with SIRT and modern chemotherapies.
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Background
Pancreatic cancer is the fourth leading cause of cancer-
related deaths in the USA and the fifth leading cause of
cancer deaths in Europe with the incidence continuing to
rise [1, 2]. The majority of patients have locally advanced
and/or metastatic disease at presentation, resulting in a
dismal 5-year survival rate of less than 5 % [3]. At the time
that this study was conducted, gemcitabine was the most
widely used systemic treatment for metastatic pancreatic
cancer. In a phase III study, gemcitabine had a modest sur-
vival benefit of 5.6 months compared with 4.4 months for
5-fluorouracil (5FU) [4], and so the rationale for treatment
with gemcitabine was primarily the alleviation of disease-
related symptoms rather than extending overall survival
(OS) [4]. Since then, the landmark European PRODIGE-4
trial with combined chemotherapy with folinic acid, fluoro-
uracil, irinotecan and oxaliplatin (FOLFIRINOX) has
extended the OS of patients with metastatic pancreatic
cancer beyond 10 months (11.1 months vs. 6.8 months
with gemcitabine) [5]. However, despite improvements in
the control of locally advanced and metastatic disease with
FOLFIRINOX [5–7], a recent published multicentre evalu-
ation showed that Zapproximately one-third of patients
were hospitalised due to adverse events [8] and it remains
uncertain how widely this regimen will be used in the rou-
tine management of pancreatic cancer.
Liver metastases are a dominant cause of treatment fail-
ure in pancreatic cancer, occurring in 25–53 % of patients
even after loco-regional control with chemo-radiation and
surgical resection [9]. For patients with advanced disease,
the PRODIGE-4 trial showed hepatic metastases and de-
clining liver function (defined by albumin levels <3.5 g/dL)
remain independent adverse prognostic factors for OS [5].
Consequently, liver-directed therapies, which improve dis-
ease control in the liver, may be of value in extending OS
when combined with systemic chemotherapy.
Selective internal radiation therapy (SIRT) with yttrium-
90 (90Y)-labelled microspheres is a loco-regional treatment,
which has been evaluated in patients with hepatocellular
carcinoma [10–12], as well as liver-dominant neuroendo-
crine tumours [13, 14], colorectal cancer (CRC) [15–18]
and breast cancer [19–21]. To date, however, there have
been very limited published data on SIRT in pancreatic
cancer [22, 23]. Following the positive experience with
SIRT in these primary and secondary hepatic neoplasms,
we conducted a prospective study to assess whether SIRT,
combined with 5FU, would extend PFS in the liver, and
consequently OS, in patients with liver-only or liver-
dominant advanced pancreatic cancer.
Methods
Study design
This was a prospective, open-label, multicentre, phase II
trial to assess the safety and efficacy of SIRT combined with
5FU in patients with recently diagnosed liver-dominant me-
tastases from pancreatic adenocarcinoma. Enrolled patients
were to have liver metastases as the dominant clinical issue
and the site of disease that threatened the patient’s life. This
criterion was created with the expectation that enrolled pa-
tients would have bulky liver metastases, and small volume
or no extra-hepatic disease.
Patients received SIRT using 90Y-resin microspheres
(SIR-Spheres; Sirtex Medical Limited, Sydney, Australia)
as a single procedure, 2 days after the first bolus injec-
tion of 5FU 600 mg/m2 (administered once weekly). Pa-
tients with on-going response could continue to receive
chemotherapy for 16 weeks, until disease progression or
unacceptable toxicity. At the time the protocol was writ-
ten the standard treatment options for metastatic pan-
creatic cancer were gemcitabine and 5FU. Given the
safety data for the combination of 5FU and SIRT and in
order to avoid the well-documented radiosensitising ef-
fects of gemcitabine [24, 25] initial therapy was with
5FU alone, Investigators had the option after 8 weeks of
5FU to switch patients to gemcitabine 1000 mg/m2
(given weekly for 7 weeks followed by a 1-week rest, and
thereafter weekly for 3 weeks, every 4 weeks) provided
that the patient had not progressed on or experienced
unacceptable toxicity from gemcitabine previously.
The principal aim of the study was to evaluate hepatic
disease control, using PFS in the liver as the primary
endpoint. The combination of SIRT and chemotherapy
would be considered to be of clinical significance if the
median PFS in the liver was ≥16 weeks. This was based
on data from a study of 5FU alone, where more than
70 % of patients had disease progression by 2 months
[4], suggesting that if median PFS in the liver was more
than twice this it would suggest significant impact from
the addition of SIRT. The secondary endpoints were:
safety and toxicity, PFS at any site, best objective re-
sponse rate in the liver and at any site, site of disease
progression and OS.
The study conformed to the World Medical Associ-
ation Declaration of Helsinki and the Australian
National Health and Medical Research Council state-
ment on human experimentation. Prior approval of
the study protocol was received from each institute’s
Human Research Ethics Committee (Melbourne Health
Ethics Committee study 2006.124 and Mount Hospital
Ethics Committee study EC35.3).
Patients
Patients were enrolled at two centres (Mount Medical
Centre, Perth, Australia; Western Hospital, Melbourne,
Australia) between October 2006 and November 2009.
All patients were fully informed of the nature of the trial
and signed an informed consent document.
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Patients were included in the study if they were 18 years
of age or older, with a life expectancy of ≥2 months with-
out any active treatment, had a World Health Organization
(WHO) performance status of 0 or 1, and a diagnosis of
pancreatic adenocarcinoma. At the time of inclusion, the
liver had to be the dominant site of disease, impacting on
patients’ health-related quality of life and/or survival; low-
volume extra-hepatic metastases and/or an intact primary
cancer were permitted. Previous chemotherapy, either as
adjuvant treatment or first-line therapy for metastatic dis-
ease was permitted. All laboratory parameters had to be
within the defined limits for the safe delivery of SIRT, i.e.
neutrophil count >1.5 × 109/L; platelets >100 × 109/L; cre-
atinine <150 μmol/L; bilirubin ≤1 × upper limit of normal
(ULN); albumin ≥3 g/dL. Female patients were either post-
menopausal, sterile, or if sexually active using an acceptable
method of contraception. Male patients, if sexually active
(and not surgically sterile) and having a pre-menopausal
partner, were required to use an acceptable method of
contraception.
Patients were excluded with evidence of ascites, cir-
rhosis or portal hypertension (as determined by clinical
or radiological assessment), occlusion of the main portal
vein, central nervous system metastases, prior radiother-
apy that included the liver in the treatment field, prior
treatment with an investigational agent within 30 days of
SIRT, or evidence of any concurrent condition that, in
the opinion of the investigator, would render the patient
ineligible for treatment according to this protocol.
Assessment and data handling
All baseline assessments were carried out within 29 days of
enrolment, including serum cancer antigen 19-9 (CA19-9),
and computed tomography (CT) or magnetic resonance
imaging (MRI) to assess the extent of disease in the abdo-
men and chest. The percentage tumour burden within the
liver was determined using the baseline CT/MRI scan, uti-
lising validated tumour volumetry software (MeVis Distant
Services, Bremen, Germany). Patients underwent a baseline
hepatic angiogram to map the vascular anatomy of the
liver. Technetium-99 m macroaggregated albumin was
used as a surrogate for 90Y-resin microspheres during the
pre-treatment planning to determine the presence and
magnitude of arterio-venous shunting to the lungs so that
the lung radiation exposure could be kept within safe limits
(<25 Gy) and the activity of 90Y administered was adjusted
accordingly [25]. The calculated activity of 90Y to be im-
planted was determined from tables provided by the manu-
facturer, based on a modification of the Body Surface Area
formula and adjusted for the extent of lung shunting for
each patient (see Additional file 1).
Post-SIRT, patients were evaluated every 4 weeks and
tumour response was assessed every 8 weeks until dis-
ease progression in the liver according to Response
Evaluation Criteria In Solid Tumours (RECIST) version
1.0. Complete response or partial response (PR) of liver
metastases were confirmed by a further CT scan per-
formed after 4 weeks. Patients were analysed according
to the presence or absence of the primary tumour in situ
and the presence or absence of extra-hepatic metastases.
PFS in the liver was defined as the interval between
trial entry and the date of tumour progression (based on
RECIST) or death, whichever occurred sooner. OS was
defined as the interval between enrolment and the date
of death.
Adverse events were recorded from consent until
30 days after the last dose of protocol chemotherapy was
administered. At the time of their occurrence, the causal
relationship between the adverse events and the protocol
therapy was recorded by the investigator. All adverse
events were graded using the National Cancer Institute
Common Terminology Criteria for Adverse Events
(NCI-CTCAE) version 3.0. Adverse events are presented
according to time of occurrence: from enrolment up to
day 60 or beyond day 60.
Statistical analysis was conducted using Microsoft Excel
(Microsoft Corporation, Redmond, Washington, USA). PFS
and OS was summarised by the Kaplan-Meier method
using nonparametric estimates of the survivor function.
Results
Baseline characteristics and treatment
Fifteen patients were enrolled and received protocol ther-
apy. One patient was excluded from the analysis after the
histopathology report confirmed retrospectively that the
liver lesion was derived from a pancreatic neuroendo-
crine tumour. Patient and disease characteristics for
the remaining 14 patients are detailed in Table 1. Pa-
tients entered the study a median of 13 days after diag-
nosis of metastatic pancreatic cancer. Most patients
had a good performance status, either WHO 0 (71 %)
or 1 (29 %). The primary cancer was in situ in ten pa-
tients (71 %); six of these patients had liver-only metas-
tases, and four had extrahepatic disease/metastases
(EHD). The primary tumour had been resected in four
patients (two with liver-only disease; two with EHD).
Three patients had received prior chemotherapy (three
received gemcitabine, two 5FU, one carboplatin); all
three had liver-only metastases, two with a resected
primary. The tumour burden in the liver varied be-
tween 1 and 37 % of the liver volume (mean 14 %), with
bilobar involvement in all patients.
All patients received SIRT 2 days after the first weekly
dose of 5FU. The median prescribed and administered
activity of 90Y-resin microspheres was 1.1 GBq (range
0.7–2.0 GBq). 90Y-resin microspheres were administered
by selective injection to left and right hepatic arteries ex-
cept in one patient who did not receive SIRT in the right
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lobe due to an unfavourable hepatic arterial anatomy
that precluded catheter access. Median follow-up from
study entry was 5.9 months (range 1.4–16.2 months).
Patients received a median of 8 weekly doses of 5FU
(median 600 mg/m2; range 350–638 mg/m2). Seven pa-
tients (50 %), one of whom had progressive disease, re-
ceived a median of 2 doses (range 2–10) of gemcitabine
(median 1000 mg/m2; range, 600–1000 mg/m2), an aver-
age of 3.7 months (range 2.1–8.1 months) after the start
of 5FU.
Adverse events
Adverse events are listed in Table 2A and B. The major-
ity of adverse events occurred during the first 60 days of
therapy.
Early events (days 0–60): grade 3/4 adverse clinical and/
or laboratory events occurred in 8 (57 %) patients during
this period. Nine patients (64 %) had no grade 3 or higher
treatment-related clinical adverse events, and there was
no grade 3 or 4 abdominal pain, nausea, vomiting or diar-
rhoea during this period. Two patients (14 %) developed
grade 3 fatigue which may have been treatment-related.
Grade 3 biochemical toxicities were observed in two pa-
tients (14 %) and significant haematological events in four
patients (28 %): grade 3 neutropenia (two patients; 14 %)
and grade 3 thrombocytopenia (two patients; 14 %).
Later events (after 60 days): six patients (50 %) had grade
3 or higher treatment-related clinical adverse events, four
of whom had switched to gemcitabine, with biochemical
toxicities reported in six patients (50 %, three on gemcita-
bine) and hematologic events in three patients (25 %, all on
gemcitabine).
Death without documented progression occurred in two
patients. The first patient died suddenly 1.5 months after
study entry and within 28 days of SIRT; the patient had
no adverse events greater than grade 1 severity, laboratory
tests were within normal limits but CA19-9 had increased
by 293 % from baseline. At enrolment, this patient had a
T4 primary tumour in situ with metastases to the liver,
lungs and lymph nodes. The second patient, who died
7.0 months after study entry, presented with liver-only
metastases following prior resection of a T2 primary can-
cer. The patient died from hepatic failure, considered to
possibly be due to radioembolization-induced liver disease
Table 1 Baseline patient and disease characteristics
Characteristics Patients
Number Percentage
Gender Male 6 43 %
Female 8 57 %
Age, years; median (range) 62 (48–76)
WHO performance status 0 10 71 %
1 4 29 %
Time from diagnosis of metastatic pancreas cancer to trial entry, adays; median (range) 13 (5–434)
Cancer stage at diagnosis TX 4 29 %
T2 6 43 %
T3 2 14 %
T4 2 14 %
Primary tumour in situ Yes 10 71 %
No 4 29 %
Metastases Liver only 8 57 %
Liver and lung 2 14.5 %
Liver and lymph nodes 2 14.5 %
Liver, lung and lymph nodes 1 7 %
Liver, lung, lymph nodes, soft tissue 1 7 %
Number of metastatic sites; median (range) 3 (1–5)
CA19-9, bU/mL; median (range) 3480 (33–280,000)
>ULN 13 93 %
Prior lines of chemotherapy for metastatic disease 0 13 93 %
1 1 7 %
aTrial entry defined as day of informed consent
bN = 13 patients with elevated CA19-9 baseline levels (ULN 37 U/mL)
Gibbs et al. BMC Cancer  (2015) 15:802 Page 4 of 12
Table 2 Adverse events. Adverse events (by NCI-CTCAE v.3 grade) recorded up to 60 days after the start of protocol therapy, from
61 days onwards and across the whole study period (n = 14)
Category/event Day 1 to 60 (n = 14) Day 61 onwards (n = 12) Day 1 to last assessment (n = 14)
Grade 1–2 Grade ≥3 Grade 1–2 Grade ≥3 Grade 1–2 Grade ≥3
A.
Gastrointestinal
Nausea 10 0 4 1 10 1
Vomiting 7 0 1 0 8 0
Anorexia 5 0 5 2 6 2
Diarrhoea 4 0 1 1 4 1
Stomatitis 1 0 2 0 2 0
Mucositis 2 0 0 0 2 0
Constipation 2 0 1 0 2 0
Pain
Abdominal pain 2 0 1 0 3 0
Pain (non-abdominal) 0 1 0 0 0 1
Constitutional Symptoms
Fatigue 6 2 5 5 4 6
Fever 3 0 0 0 3 0
Hepatobiliary/Pancreas
Ascites 0 1 0 3 0 3
Jaundice 0 0 0 1 0 1
Liver failure 0 0 0 1 0 1
Neurology
Neuropathy 3 0 1 0 3 0
Pulmonary/Upper Respiratory
Dyspnoea 1 1 1 1 1 1
Bruising 1 0 2 0 2 0
Pneumonia 0 1 1 0 0 1
Vascular
Pulmonary embolism 0 1 0 0 0 1
Deep vein thrombosis 0 1 0 1 0 1
Dermatology/Skin
Dry skin/cracked skin 1 1 0 1 1 1
Haemorrhage/Bleeding
Epistaxis 1 0 2 0 2 0
Ocular/Visual
Epiphora 3 0 3 0 3 0
B.
Biochemical/Laboratory
Hyperbilirubinemia 5 3 2 6 4 7
Albumin 9 1 8 1 11 1
Alkaline phosphatase 4 1 8 0 8 1
Alanine transaminase 8 0 5 0 10 0
Aspartate aminotransferase 3 0 5 0 6 0
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(REILD), although the role of prior gemcitabine and
herbal remedies prior to protocol therapy should also
be considered. The patient had also received external beam
radiotherapy (45 Gy in 25 fractions) to the pancreas.
Treatment response and survival
Individual best response within the liver (according to
RECIST) is presented in the waterfall plot together with
the tumour characteristics and CA19-9 response (Fig. 1).
A PR in the liver was recorded in three patients (21 %)
(2 confirmed; 1 unconfirmed) and stable disease (SD) in
ten patients (71 %), giving a liver disease control rate of
93 %. CT scans of a patient with a partial response are
shown in Fig. 2. Best response (at all sites) was 1 PR
(7 %), SD in nine patients (64 %) and progression in four
patients (29 %). Median reduction in CA19-9 was 72 %.
Switching to gemcitabine did not appear to contribute
to the initial response.
The median liver PFS was 5.2 months (range 1.4–
17.7 months), which exceeded the pre-specified threshold
for clinical significance, and 4.4 months (range 1.4–
16.3 months) at any site (Fig. 3). The median time to pro-
gression in the liver was derived by per protocol follow-up
scans on all patients until progression of liver metastases,
including patients who had progressed outside the liver
as the first site of progression and may have commenced
a second line of chemotherapy. PFS at any site was
shorter in patients with advanced primary tumour in situ
compared with those who had their primary tumour
resected (median 3.4 vs. 7.8 months; p = 0.017; Fig. 4).
Two patients with liver-only metastases and a resected
primary had an overall PFS of 16.3 and 7.0 months,
respectively.
The first site of progression is listed in Table 3. The liver
was the first site of progression in two patients: one with
new lesions at 6.5 months and one with progression of
Table 2 Adverse events. Adverse events (by NCI-CTCAE v.3 grade) recorded up to 60 days after the start of protocol therapy, from
61 days onwards and across the whole study period (n = 14) (Continued)
Blood/Bone Marrow
Haemoglobin 7 0 3 0 8 0
Platelets 4 2 5 2 4 4
Leukocytes 8 1 2 0 8 1
Neutrophils 2 2 1 1 2 2
A) Any grade 1–2 treatment-related adverse clinical events occurring in >10 % of patients and all grade 3–4 treatment-related adverse clinical events. B) All-cause
laboratory events
Fig. 1 Percentage change from baseline in the sum of index lesions in the liver. Waterfall plot of percentage change from baseline in the sum of
index lesions in the liver, with pancreatic lesion response, CA19-9 response and tumour characteristics. § Patients switching protocol chemotherapy
to gemcitabine 2.1–8.1 months after the start of 5FU (red asterisk); † Tumour response by RECIST v1.0 (change while on 5FU in blue; change while on
gemcitabine in red); nm: non-measurable disease; ‡ baseline value < ULN (excluded from analysis of mean change in CA19-9)
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existing liver lesions at 8.5 months after enrolment. Three
patients (21 %) deteriorated clinically without documented
evidence of disease progression. Two patients (13 %) were
withdrawn from study treatment due to adverse events:
one with grade 2 nausea/vomiting 3.6 months after
study entry and 1 week after commencing gemcitabine,
and the other with obstructive jaundice and ascites, at
2.7 months post-enrolment and 2 weeks after switching
to gemcitabine.
Median OS was 5.5 months (range 1.4–19.5 months)
for the entire cohort (Fig. 5) and 12.2 months (range
7.0–17.7 months) for patients with disease confined to
the liver. Unplanned subgroup analysis revealed signifi-
cantly longer survival in patients whose primary
tumour had been resected (n = 4; median 13.6 vs.
4.2 months; p = 0.015; Fig. 6). For patients with liver-
only metastases (n = 8), median survival was 6.6 months
(range 3.6–17.7 months; Fig. 7). Where patients had
EHD (n = 6), the median survival was 4.6 months
(range 1.4–19.5 months). A summary of the character-
istics of patients alive after 12 months is shown in
Table 4.
Discussion
Metastatic pancreatic cancer carries a very poor prognosis.
Progress has been frustratingly slow with numerous
agents in combination with gemcitabine demonstrating
promise in phase II studies, but minimal impact on OS in
subsequent phase III randomised trials. Limited benefit
has been demonstrated with the addition of oxaliplatin
[26], cisplatin [27], capecitabine [28, 29], cetuximab [30],
bevacizumab [31] or erlotinib [32] to gemcitabine. A re-
cent study demonstrated a significant improvement in OS
with FOLFIRINOX, but uncertainty remains as to whether
this can be safely achieved in routine clinical practice [5].
In this first prospective study of the safety and efficacy
of SIRT in advanced pancreatic cancer, 5FU rather than
gemcitabine was administered concomitantly with 90Y-
resin microspheres, thereby circumventing any potential
adverse events associated with gemcitabine radiosensitisa-
tion of non-target tissue. Overall, the spectrum of adverse
events in this study associated with SIRT (characterised by
mild-to-moderate abdominal pain, nausea, and transient
changes in liver function) and 5FU (neutropenia and
thrombocytopenia) were similar to those reported in
several previous trials in patients with liver metastases
from CRC, in which this combination has been demon-
strated to be safe [15, 16]. The incidence of grade 3/4
haematological toxicities (14 %) was consistent with the
past experience with SIRT and 5FU [15, 16]. Patients
who received gemcitabine no sooner than 8 weeks
post-SIRT experienced a similar rate of adverse events
as would be expected from gemcitabine therapy alone [4],
without any evidence of REILD [33]; suggesting that gem-
citabine can safely be given after SIRT.
In this study, one responding patient on 5FU developed
signs suggestive of REILD and died at 7.0 months after
treatment. REILD is defined as jaundice and ascites in the
absence of tumour progression or bile duct obstruction
commencing within 8 weeks of SIRT [33], so this event
occurred well outside that window. Both rising bilirubin
levels (from grade 2 on day 39 to grade 4 on day 102) and
elevated alkaline phosphatase levels (which were greater
than grade 1 from day 116 onwards) are recognised hall-
marks of REILD [33]; although the clinical picture in this
patient was complicated by use of herbal remedies [34]
and gemcitabine pre-SIRT, which may have contributed to
liver failure in this case as may have disease progression.
The sudden death observed in one other patient was con-
sidered unlikely to be related to SIRT as sudden deaths on
SIRT have not previously been reported, and the only
Fig. 2 Tumour response in a patient with liver-only metastases from
primary pancreatic adenocarcinoma. a Contrast-enhanced CT scan
prior to SIRT + 5FU. b) Follow-up contrast-enhanced CT scan 3 months
post-SIRT + 5FU, and prior to gemcitabine, demonstrates a partial
response (40 % reduction in hepatic tumour burden), as assessed
according to RECIST v1.0
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likely cause of treatment related death (liver failure) is
usually of slow onset with clinical and laboratory signs evi-
dent well in advance of patients dying.
Tumour response within the liver was encouraging, with
21 % of patients (three out of 14) achieving a confirmed or
unconfirmed PR and 71 % (ten out of 14) achieving SD, by
RECIST criteria, for a disease control rate of 93 %. As
shown in Fig. 1, the size of the liver lesions diminished in
all but one of the 13 patients who had post-SIRT imaging
at 8 weeks intervals and no patient had progressive disease
within the liver on initial follow-up CT imaging. With lim-
ited radiological response on gemcitabine, it would seem
reasonable to conclude that the recorded response was
largely due to the protocol treatment rather than subse-
quent gemcitabine.
The imaging results are also corroborated by the de-
cline in CA19-9 observed in 12 of 13 patients with an
elevated CA19-9 at baseline, including all but one of
those with EHD. Similar to the experience in SIRT-
treated CRC liver metastases [35, 36], the decline in
tumour marker was rapid and appeared to predict later
CT response and PFS.
The results of our phase II study compare favourably to
a time to progression in the randomised controlled trial
by Burris et al. of 0.9 months for 5FU alone, and
2.3 months for gemcitabine and response rate with 5FU
alone of 0 and 19 % SD. Subsequently Cunningham et al.
has recorded small incremental improvements in PFS with
gemcitabine combined with capecitabine compared with
gemcitabine alone (5.3 vs. 3.8 months), which have been
accompanied by a small survival benefit (6.2 vs.
7.1 months) [29]. The median PFS reported for patients
treated with FOLFIRINOX in the recent randomised
study was 6.4 months [5]. Significantly however, the stud-
ies by Cunningham et al. [28] and that of Burris et al. [4]
included many patients with locally advanced disease (29
and 26 % of patients, respectively), for whom the median
PFS would be expected to be superior, whereas the
current study and the FOLFIRINOX study only included
patients with metastatic disease.
As expected for a liver-directed therapy, studies of SIRT
in patients with CRC have demonstrated better outcomes
in patients with disease confined to the liver [18, 37]. In
Fig. 3 Kaplan-Meier analysis of PFS and OS. 3) PFS in the liver and at any site. 4) PFS at any site stratified by the presence or absence of the primary
tumour in situ. 5) OS. 6) OS stratified by the presence or absence of the primary tumour in situ. 7) OS stratified by the presence of liver-only metastases
or liver plus EHD
Table 3 Site of first progression (n = 14)
Location of first progression Patients
Number Percentage
Documented progression on CT
Liver 2 20
Lung 2 13
Lymph node 1 7
Peritoneum 1 7
Pleural effusion 1 7
No progression documented
Clinical deterioration 3 20
Death without progression 2 13
Withdrawn due to adverse events 2 13
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the current trial, outcomes likewise appeared related to
extent of disease outside the liver, with the best results
seen in the two patients with liver-only disease (OS of 7.0
and 17.7 months) and the worst outcomes in the four pa-
tients with an intact primary and liver metastases plus
EHD (median OS of 4.2 months). These results suggest
that further studies of SIRT in pancreatic cancer liver me-
tastases should be confined to the population of patients
with liver-only disease who have had their primary lesion
resected or who have well-controlled primary disease.
These analyses should not be used to select patients for
treatment outside of clinical trials, as SIRT remains an ex-
perimental treatment option in this disease type.
Conclusions
The data obtained from this study of the combination of
SIRT and 5FU in the treatment of liver metastases from pri-
mary pancreatic cancer demonstrated evidence of effective
Fig. 5 Kaplan-Meier analysis of PFS and OS
Fig. 4 Kaplan-Meier analysis of PFS and OS
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disease control of liver metastases from pancreatic adenocar-
cinoma, with a disease control rate of 93 % and a liver PFS
of 5.2 months. However, the combination of SIRT and 5FU
resulted in a toxicity profile that was significant and the
safety of this approach in patients with metastatic pancreatic
cancer will need to be confirmed in subsequent studies. This
combination of therapy is likely to be of most benefit in se-
lected patients with a resected primary tumour and liver
only disease. Ultimately though, randomised trials will be
needed to prove the role of SIRT in combination with
chemotherapy in metastatic pancreatic cancer, and to define
the patients who will most benefit from this treatment. Strat-
egies combining SIRT with gemcitabine are likely to be lim-
ited by the doses of gemcitabine that could be given safely
with SIRT, without compromising its systemic activity.
Several studies in CRC have demonstrated that SIRT
Fig. 7 Kaplan-Meier analysis of PFS and OS
Fig. 6 Kaplan-Meier analysis of PFS and OS
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can be safely combined with FOLFOX [15–17] and with
irinotecan [38], suggesting that initial cycles with FOL-
FOX or irinotecan might be an attractive strategy.
Human research and ethics committees approval
This study was approved by the ethics committees of
Melbourne Health, Parkville, Australia (for patients en-
rolled at Western Hospital) and Mount Hospital, Perth,
Australia (for patients enrolled at Mount Hospital)
Additional file
Additional file 1: Dosimetry tables for 90Y-resin microspheres. The
following tables (Table S1A to S1C) provided by Sirtex Medical Limited,
Sydney, Australia were used in this phase II study to guide the dosimetry
for 90Y-resin microspheres (SIR-Spheres). The tables, based a modification
of the Body Surface Area (BSA) formula, calculated the activity in
gigabecquerels (GBq) of 90Y which was to be implanted determined
from the BSA and percentage tumour involvement of whole liver for
each patient. Three tables were provided so that the implanted activity
of 90Y could be further adjusted for each patient according to extent of
lung shunting (0–10 %; 11–15 %; 16–20 %). The tables provide a more
user-friendly method for calculating the dosimetry for 90Y-resin microspheres,
while at the same including slight modifications to the dosing, in order to
improve the safety of this procedure in patients with either a very low
(<10 %) or high (>60 %) tumour volume in the liver. (DOCX 43 kb)
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